The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Insights into the real-world REVIVE study: venetoclax-based low-intensity therapy in AML
Yakir Moshe, MD, PhD, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, shares insights into the real-world REVIVE study (NCT03987958) examining venetoclax-based low-intensity protocols in patients with acute myeloid leukemia (AML). Dr Moshe highlights that the findings support individualized rather than universal prophylaxis use, suggest a trend toward improved overall survival with G-CSF, and demonstrate the feasibility of outpatient management in carefully selected patients. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
